DivestmentApr 22, 2026, 07:02 AM
Certara Sells Regulatory & Medical Writing Business for up to $135M
AI Summary
Certara, Inc. announced a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for up to $135 million. This divestment aims to sharpen Certara's focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions, accelerating investment in AI-integrated modeling and simulation. The divested business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025 and is expected to close in Q2 2026.
Key Highlights
- Certara to sell Regulatory and Medical Writing business for up to $135 million.
- Business generated $50 million in revenue and $17 million adjusted EBITDA in 2025.
- Transaction expected to close in Q2 2026.
- Approximately 220 employees are part of the divested business.